Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

RegulatoryModzatinibPositive

AI Analysis

Summary

Aclaris Therapeutics announced that modzatinib (ATI-2138) has received Fast Track Designation from the FDA for the treatment of moderate to severe lichen planus. This designation expedites the development and review process for the drug candidate.

Outcome Details

Fast Track Designation granted

Importance:6/10

Sentiment:

0.70

Fast Track DesignationDermatologyRegulatory Approval Pathway

Related Companies

$ACRS

Read the original article

Published by yahoo_finance on August 6, 2026 8:35 PM

Read Original